Aptamir Therapeutics

AptamiR Therapeutics is a biotechnology company founded in 2012, dedicated to developing revolutionary treatments for human obesity. Based on an innovative strategy targeting subcutaneous fat cells rather than the central nervous system or intestinal food absorption, AptamiR is developing microRNA-targeted therapies that promote thermogenesis, converting white fat-storing adipocytes into fat-burning adipocytes (brown-like, brite, or beige). MicroRNAs are attractive drug candidates for complex diseases such as obesity because they can regulate the expression of gene networks. AptamiR has also developed drug delivery methods that specifically target microRNA modulators to adipose tissue.